Next generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. As a result, their commercial potential is significant; however they are significantly more cost intensive.
As a result, attempts are being made to optimize the workflow to increase antibody yield whilst reducing the development costs.
Download this eBook to explore:
Brought to you by: